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Introduction {#sec005}
============

Cerebral ischemic stroke is a leading cause of long-term disability worldwide. After ischemia, the neuron cells may activate multiple death cascades, including apoptosis, necrosis, and autophagy. However, several neuroprotective mechanisms have been identified to reduce neuronal injury and alleviate the insult after ischemic stress \[[@pone.0139608.ref001],[@pone.0139608.ref002]\]. Estrogen is one of them to promote neuronal survival and reduce disability in patients with ischemic stroke \[[@pone.0139608.ref003],[@pone.0139608.ref004]\].

In addition to acting as a "sex hormone", estrogen has been documented to provide a multifaceted modulation of neurons, including plasticity and neuroprotection in stroke \[[@pone.0139608.ref003],[@pone.0139608.ref004]\]. Most of estrogen's actions are exerted via nuclear receptors and estrogen receptor alpha (ERα) is the most important one for estrogen-mediated neuroprotection following focal cerebral ischemia \[[@pone.0139608.ref005]\]. In experimental stroke models, the estrogen protective effect is lost in the ERα knockout mice \[[@pone.0139608.ref006]\]. Additionally, mRNA and protein levels of ERα are significantly increased in the cortex of middle cerebral artery occlusion (MCAO) mice \[[@pone.0139608.ref007]\]. These findings suggest that the ERα is a critical link in mediating the protective effects of estrogen in ischemic brain injury.

DNA methylation is a major type of epigenetic regulation that affects disease pathogenesis. In adult non-gamete cells, DNA methylation typically takes place in a cytosine--guanine (CpG) dinucleotide context, also known as a CpG site. In general, DNA methylation will silence gene expression. The DNA methylation status can be altered by environmental changes \[[@pone.0139608.ref008]\]. Accumulating evidence has indicated that an increased methylation level in the ERα promoter region is negatively associated with ER expression in several diseases, including breast cancer, prostate cancer, and atherosclerosis \[[@pone.0139608.ref009]--[@pone.0139608.ref011]\]. The methylation of the ERα gene involved in ischemic stroke has drawn attention in a rodent stroke study recently \[[@pone.0139608.ref012]\]. Westberry et al have found that the methylation level of ERα decreased following MCAO induction in rats. Interestingly, brain ischemic that leads to demethylation in the ERα promoter only occurs in female rats, but not in male rats \[[@pone.0139608.ref012]\]. However, the effect of methylation levels in the ERα promoter region has not yet to be explored among ischemic stroke patients.

This study aims to investigate the level of ERα methylation in the peripheral blood of ischemic stroke patients. As the disease severity and outcome varied among stroke subtypes \[[@pone.0139608.ref013]\], we also examined the methylation status of the ERα gene in different stroke subtypes. Since gender might have an influence on the ERα genetic predisposition, we assessed the methylation level of ERα between male and female patients.

Materials and Methods {#sec006}
=====================

Subjects {#sec007}
--------

### Stroke subjects {#sec008}

Patients of ischemic stroke with ages between 40 and 80 years old were selected from our existing patient cohort, all of whom enrolled from the Kaohsiung Medical University Hospital and the Taichung Veterans General Hospital in Taiwan \[[@pone.0139608.ref014]\]. These cases were selected using the following criteria: (1) stroke subjects in our existing cohort were selected only when the first stroke event occurred before age 80, (2) stroke cases were divided into four age groups (40--50 y/o, 51--60 y/o, 61--70 y/o, 71--80 y/o), and (3) equal number of male and female stroke patients were selected from each age group randomly. The available DNA samples were checked from the selected patients and the final 201 patients were included in this study. All patients had a standard stroke investigation that included laboratory examination and cranial computed tomography (CT) or magnetic resonance imaging (MRI). Ischemic stroke status was established when the brain imaging revealed acute infarction and showed no evidence of hemorrhage. Stroke subtypes were classified based on the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) \[[@pone.0139608.ref015]\].

### Control subjects {#sec009}

The healthy controls were selected from the subjects of self-reported stroke- and myocardial infarction (MI)-free volunteers recruited at the Kaohsiung Medical University Hospital through an advertisement soliciting volunteers \[[@pone.0139608.ref016]\]. Two hundred and seventeen age- and sex-comparable controls were selected by a table of random numbers. To minimize the age effect, we tried to select an equal number of cases and controls from each age group. We performed the above procedure for men and women separately to minimize gender confounds. The random number tables were generated by the SPSS statistical software.

For each participant, socio-demographic information and medical history of hypertension, diabetes, hyperlipidemia, and cigarette smoking were obtained. Total cholesterol, triglycerides, and glucose levels were measured from venous blood after fasting for at least 8 hours. Hypertension was defined as systolic or diastolic blood pressure ≥140/90 mm Hg or anti-hypertensive medication use. Diabetes was defined as fasting blood glucose ≥126 mg/dl or known treatment for diabetes. Hypercholesterolemia was defined as serum levels of total cholesterol ≥200 mg/dl or use of lipid lowering medication. The Kaohsiung Medical University Hospital and the Taichung Veterans General Hospital Institutional Review Boards approved the study and every participant provided written informed consent.

Genomic DNA extraction and detection of ERα methylation {#sec010}
-------------------------------------------------------

Genomic DNA was isolated using a commercially available DNA extraction kit (Gentra; Qiagen, Hilden, Germany). DNA sample was then treated with sodium bisulfate, converting unmethylated cytosine (C) to uracil and leaving methylated C intact, by using an EpiTect Fast Bisulfite Kit (Qiagen) following the manufacturer's recommendations. The completion of bisulfite treatment was assayed by detecting unconverted bisulfite cytosine outside the CpG based on the assumption of non-CpG cytosines were mainly unmethylated. The method for the assessment is as follow: the pyrosequencer PyroMark Q24 has a feature that acts as quality control for complete bisulfite conversion of DNA. When the assay encounters a unmethylated C not followed by a guanine (G), that C should be fully converted to thymine (T) after bisulfite treatment and PCR, if the bisulfate treatment upfront was successful. Subsequently, it should be presented in the pyrogram as T = 100%. On the other hand, if the non-CpG cytosine is methylated, the methylated C will not be eventually converted to T. Accordingly, the pyrogram from the assay will not yield a perfect conversation to T and instead a "Failed" quality assessment will be assigned by the Q24 software. This acts as a useful quality control for full conversion of unmethylated C residues during bisulfite treatment and PCR. We assessed the completion of bisulfite treatment at all eight non-CpG cytosines in our sequence region in 10 randomly selected samples. All non-CpG cytosine showed fully bisulfite conversion.

The original ERα methylation assay was designed by PyroMark Assay Design 2.0 software (Qiagen) to cover 20 CpG sites in the CpG island of the ERα promoter. The bisulfite-modified DNA was used to amplify the 187-bp product in the promoter of ERα gene ([Fig 1](#pone.0139608.g001){ref-type="fig"}) (primers are shown in [S1 Table](#pone.0139608.s001){ref-type="supplementary-material"}). The quantitative ERα methylation level at the CpG sites was evaluated via pyrosequencing (PyroMark Q24;Qiagen). Universal unmethylated and methylated DNAs were run as controls. Methylation quality check and quantification were performed using the PyroMark Q24 2.0.6 software (Qiagen). The level of ERα methylation was quantified as percentage of methylated cytosine within the sum of methylated and unmethylated cytosines.

![Schematic diagram of the distribution of CpGs in estrogen receptor α promoter CpG island.](pone.0139608.g001){#pone.0139608.g001}

Statistical analysis {#sec011}
--------------------

Student's t-test and chi-square test were used to analyze the characteristics of study subjects. Analysis for an association between the ERα methylation level and the phenotypes of interest (stroke as a whole and stroke subtypes) was first performed using the Student's t-test. Multivariate logistic regression analysis was conducted to adjust for sex, age, smoking, hypertension, diabetes, and hypercholesterolemia. We also analyzed the sex-specific effect, given that ERα methylation level was only changed in female rats \[[@pone.0139608.ref012]\]. The SPSS 18.0 version for Windows (SPSS Inc., Chicago, Illinois, USA) was used for statistical analysis. A two-sided p-value less than 0.05 was considered statistically significant.

Results {#sec012}
=======

The demographic characteristics of the study subjects are presented in [Table 1](#pone.0139608.t001){ref-type="table"}. Since the cases and controls were selected to be age- and sex-comparable, these two factors were no longer significantly different. Nevertheless, traditional risk factors such as the prevalence of hypertension, diabetes, hypercholesterolemia, and smoking were significantly higher in stroke cases than in controls, as expected. For stroke subtypes, there were 39 (19.4%) cases of large-artery atherosclerosis, 20 (10.0%) of cardio-embolism, 89 (44.3%) of small vessel occlusion, and 53 (26.4%) of undetermined etiology based on the TOAST classification \[[@pone.0139608.ref015]\].

10.1371/journal.pone.0139608.t001

###### Demographic characteristics of the study participants.

![](pone.0139608.t001){#pone.0139608.t001g}

                                  Stroke, n = 201   Controls, n = 217   *p* value
  ------------------------------- ----------------- ------------------- -----------
  Age (yr)                        60.8±10.3         61.4±11.0           0.554
  Male (%)                        101 (50.2)        101 (46.5)          0.449
  Hypertension (%)                154 (76.6)        99 (45.6)           \<0.001
  Diabetes (%)                    91 (45.3)         32 (14.7)           \<0.001
  Hypercholesterolemia (%)        102 (50.7)        59 (27.2)           \<0.001
  Current& ever smoker (%)        69 (34.3)         34 (15.7)           \<0.001
  Stroke subtype                                                        
   Large-artery atherosclerotic   39 (19.4)                             
   Cardio-embolism                20 (10.0)                             
   Small vessel                   89 (44.3)                             
   Undetermined                   53 (26.4)                             

Data are shown as mean± SD for quantitative variables and n (%) for qualitative variables

The length of our target sequence (187-bp) is longer than the suggested length (within 80--100 bp) by the manufacture, which is due to limited choices to design primers in the CG rich region. The results from pyrosequencing indicated that six sites (sites15--20) had low quality of sequence data that were excluded for further analysis. Therefore, the present study only presented data at 14 CpG sites. The methylation levels in the peripheral blood at 14 ERα promoter CpG sites in stroke cases and healthy controls are shown in [Table 2](#pone.0139608.t002){ref-type="table"}. In general, ERα methylation levels were lower among the ischemic stroke cases compared to those in the controls. The p-values at CpG site13 and site14 were significant (adjusted *p* = 0.035 and 0.026, respectively).

10.1371/journal.pone.0139608.t002

###### Association between ischemic stroke and estrogen receptor α promoter methylation level.

![](pone.0139608.t002){#pone.0139608.t002g}

           Controls, n = 217   Stroke, n = 201               
  -------- ------------------- ----------------- ----------- -----------
  Site1    5.08±2.02           4.71±2.24         0.078       0.353
  Site2    3.93±1.62           3.60±1.63         **0.043**   0.284
  Site3    5.24±2.64           4.90±3.01         0.224       0.512
  Site4    3.89±1.44           3.64±1.51         0.079       0.500
  Site5    4.34±2.10           3.88±2.01         **0.021**   0.221
  Site6    3.71±1.41           3.32±1.69         **0.012**   0.111
  Site7    4.95±1.75           4.61±2.13         0.073       0.385
  Site8    3.65±1.57           3.35±2.40         0.136       0.287
  Site9    2.93±1.10           2.64±1.47         **0.023**   0.083
  Site10   4.90±1.70           4.60±2.43         0.142       0.854
  Site11   4.76±2.21           4.27±2.05         **0.018**   0.078
  Site12   4.40±1.74           4.02±2.70         0.097       0.079
  Site13   3.05±1.60           2.60±1.13         **0.001**   **0.035**
  Site14   7.87±3.62           6.95±2.58         **0.003**   **0.026**

Adjusted p value was adjusted for age, sex, hypertension, diabetes, hypercholesterolemia, and smoking

There are differences in stroke severity and outcomes between stroke subtypes \[[@pone.0139608.ref013],[@pone.0139608.ref017]\]. Large-artery atherosclerosis and cardio-embolism are associated with a more adverse outcome and early stroke recurrence. Small vessel occlusion, on the contrary, is associated with the lowest stroke severity and mortality \[[@pone.0139608.ref013],[@pone.0139608.ref017]\]. Therefore, large-artery atherosclerosis and cardio-embolism were combined as one group (LAA/CE group) and small vessel occlusion was treated as the other group (SVO group) while we evaluated the ERα methylation status in stroke subtypes. Compared with the healthy controls, patients in the LAA/CE group had lower ERα methylation levels at all CpG positions, especially at CpG site5, site9, site12, site13 and site14 with adjusted *p* = 0.039, 0.009, 0.025, 0.046 and 0.027 respectively ([Table 3](#pone.0139608.t003){ref-type="table"}). However, no significant difference in methylation level was observed between patients in the SVO group and the healthy controls in any of the ERα CpG sites.

10.1371/journal.pone.0139608.t003

###### Stratification analysis for association between ischemic stroke subtypes and estrogen receptor α promoter methylation.

![](pone.0139608.t003){#pone.0139608.t003g}

           Control     Small vessel   Large-artery atherosclerosis and cardio-embolic               
  -------- ----------- -------------- ------------------------------------------------- ----------- -----------
  Site1    5.08±2.02   4.79±2.18      0.618                                             4.57±2.54   0.458
  Site2    3.93±1.62   3.79±1.79      0.908                                             3.43±1.62   0.339
  Site3    5.24±2.64   5.18±3.36      0.948                                             4.78±3.03   0.724
  Site4    3.89±1.44   3.81±1.64      0.745                                             3.40±1.34   0.145
  Site5    4.34±2.10   3.99±1.95      0.414                                             3.55±1.58   **0.039**
  Site6    3.71±1.41   3.40±1.70      0.272                                             3.29±2.04   0.307
  Site7    4.95±1.75   4.59±1.81      0.308                                             4.47±2.09   0.229
  Site8    3.65±1.57   3.39±2.03      0.373                                             3.37±3.30   0.485
  Site9    2.93±1.10   2.63±1.10      0.125                                             2.40±1.05   **0.009**
  Site10   4.90±1.70   4.65±2.66      0.952                                             4.60±2.48   0.841
  Site11   4.76±2.21   4.36±1.72      0.294                                             4.27±2.91   0.342
  Site12   4.40±1.74   4.09±2.18      0.400                                             3.60±1.94   **0.025**
  Site13   3.05±1.60   2.70±1.21      0.366                                             2.48±1.13   **0.046**
  Site14   7.87±3.62   7.03±2.51      0.211                                             6.68±2.48   **0.027**

Adjusted p value was adjusted for age, sex, hypertension, diabetes, hypercholesterolemia, and smoking

Since demethylation of the ERα gene following ischemic stroke was shown in female but not male rats \[[@pone.0139608.ref012]\], we further tested the sex-specific effect of ERα methylation status in the LAA/CE group. The methylation levels of five significant CpG sites shown in [Table 3](#pone.0139608.t003){ref-type="table"} (i.e. CpG site5, site9, site12, site13 and site14) were different between male and female patients ([S2 Table](#pone.0139608.s002){ref-type="supplementary-material"}). The average methylation levels of these five significant CpG sites were used for subsequent analysis. Compared with female controls, female cases had a significant lower methylation level in the ERα promoter (3.97% vs 4.68%, adjusted *p* = 0.011) ([Fig 2](#pone.0139608.g002){ref-type="fig"}). Although male cases also had a lower ERα methylation level compared with male controls, the difference was not statistically significant (4.07% vs 4.34%, adjusted *p* = 0.300).

![Sex-specific analysis for the association between estrogen receptor α promoter methylation level and large-artery atherosclerosis and cardio-embolic stroke subtypes.](pone.0139608.g002){#pone.0139608.g002}

Discussion {#sec013}
==========

The present study demonstrates that in human data, female stroke cases have lower ERα methylation levels than those in the controls, which is consistent with the previous experimental findings in stroke animals \[[@pone.0139608.ref012]\]. However, the association was primarily in the patients of LAA/CE stroke subtypes. While the patients of SVO stroke also had a lower methylation level than the control subjects, the difference did not yield statistical significance. The data imply that women suffering from a major ischemic stroke may cause a more significant change in ERα methylation levels to reduce the brain injury. This finding also suggests that treatments for ischemic stroke may vary between female and male patients. In addition, the beneficial effect of estrogen therapy in acute ischemic stroke \[[@pone.0139608.ref018]\] may require further analysis in sex-specific and stroke subtype-specific manners.

DNA methylation is a well characterized epigenetic change that contributes to transcriptional regulation \[[@pone.0139608.ref008]\]. Although aberrant DNA methylation was extensively explored in cancer studies, the importance of DNA methylation has been increasingly recognized in atherosclerosis \[[@pone.0139608.ref019],[@pone.0139608.ref020]\]. Only a few human studies have addressed the correlation between DNA methylation level and stroke \[[@pone.0139608.ref021]--[@pone.0139608.ref023]\]. Both Baccarelli et al.\[[@pone.0139608.ref021]\] and our group \[[@pone.0139608.ref023]\] found lower global methylation levels in Long Interspersed Nucleotide Element 1 (LINE-1) in the male stroke cases than controls. A higher methylation level in the promoter of the brain derived neurotrophic factor (BDNF) was reported to be associated with a poor outcome one year after stroke \[[@pone.0139608.ref022]\]. To our knowledge, this is the first human stroke study to show the ERα promoter methylation data that is consistent to the previous rodent stroke study \[[@pone.0139608.ref012]\].

The crucial role of estrogen in neuroprotection following stroke has been reported in experimental stroke models \[[@pone.0139608.ref024],[@pone.0139608.ref025]\]. It is known that the effects of estrogen on the brain following ischemic injury are largely related to regional expression of ERα \[[@pone.0139608.ref007]\]. It is also suggested that DNA methylation is a major mechanism for ERα upregulation following injury \[[@pone.0139608.ref012]\]. The ERα promoter is highly methylated in the adult rodent cortex \[[@pone.0139608.ref026]\], but the methylation level decreases dramatically and rapidly following a neuronal ischemic insult \[[@pone.0139608.ref012]\], which may account for the protective effect of estrogen in the ischemia models. Some drugs have been shown to be associated with the changes of DNA methylation *in vitro and in vivo* \[[@pone.0139608.ref027],[@pone.0139608.ref028]\]. Our laboratory recently reported that a traditional Chinese medicine can increase microRNA-152 expression, which leads to a reduction of DNA methylation in the ERα promoter \[[@pone.0139608.ref020]\]. In addition to direct use of estrogen treatment, medications that can affect ERα methylation may be clinically useful for stroke treatment.

The increased ERα expression in stroke mice occurs in neurons but not in astrocytes or microglial cells \[[@pone.0139608.ref007]\]. Stroke caused by LAA/CE subtypes generally involves a large area of cerebral cortex, whereas SVO stroke subtype involves deep cerebral white matter \[[@pone.0139608.ref029]\]. These may explain why the present study shows the significant results in the LAA/CE subtypes, but not in the SVO subtype.

The gender may have an influence not only on stroke risk but also on stroke outcomes \[[@pone.0139608.ref030]--[@pone.0139608.ref032]\]. Recently, Tian et al. found that female and male stroke patients had different gene expression patterns in the blood \[[@pone.0139608.ref033]\]. Although it is still unclear whether alterations in gene expression or epigenetic modifications in the blood of stroke patients can reflect a similar change in the brain, these data provide evidence of gender-specific changes in the DNA and RNA levels after ischemic stroke.

This study has some limitations. The current study used cross-section data and therefore the observed association might not be a causal relationship. However, our result is consistent with the report from the brain tissue of a rodent stroke study \[[@pone.0139608.ref012]\]. We explored the relationship between ischemic stroke and ERα methylation level in the genomic DNA isolated from peripheral blood rather than brain tissue. Although it may be hard to validate the correlation of methylation pattern between brain and peripheral blood, blood sample has its medical value because of easy access and better practical implications. We took the generally accepted assumption that DNA methylation almost exclusively occurred in CpG dinucleotides in mammals. Our PCR primer design was based on this assumption. However, non-CpG methylation had been reported \[[@pone.0139608.ref034]\]. The same group recently showed that PCR primer based on such an assumption might cause the underestimation of high DNA methylation \[[@pone.0139608.ref035]\]. Therefore, our approach might also underestimate the significant level if our PCR primer covered methylated non-CpG cytosines.

This study demonstrates that female patients with ischemic stroke have lower ERα methylation level. This association is especially distinctive among patients with the large vessel and embolic stroke subtypes. The results suggest that elevated ERα due to the decrease of ERα methylation level in female stroke patients may serve as a natural protective mechanism to prevent further neuronal damage.
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